Featured Post

Latest Gold News

This analyst sees nothing to stop gold from continuing climb Cyber Terrorism another reason to own gold says Faber Fed doves supportin...

Monday, November 14, 2011

Opko (OPK) (PCYC) (PXP) (QEP) (RF) (SGEN) (WMS) Get New Coverage

Opko Health Inc. (NYSE: OPK), Pharmacyclics, Inc. (NASDAQ: PCYC), Plains Exploration & Production Company (NYSE: PXP), QEP Resources (NYSE: QEP), Regions Financial Corp. (NYSE: RF), Seattle Genetics, Inc. (NASDAQ: SGEN) and WMS Industries Inc. (NYSE: WMS) getting new coverage from analysts.

Jefferies (NYSE:JEF) initiated coverage on Opko Health Inc. (OPK). They placed a “Buy” rating on the company.

Needham & Company initiated coverage on Pharmacyclics, Inc. (PCYC). They placed a “Buy” rating and a price target of $14.00 on the company.

KeyBanc initiated coverage on Plains Exploration & Production Company (PXP). They placed a “Buy” rating and a price target of $45.00 on the company.

Raymond James (NYSE:RJF) initiated coverage on QEP Resources (QEP). They placed an “outperform” rating and a $47.00 price target on the company.

BMO Capital Markets initiated coverage on Regions Financial Corp. (RF). They placed an “Outperform” rating on the company.

Needham & Company initiated coverage on Seattle Genetics, Inc. (SGEN). They placed a “Buy” rating and a price target of $20.00 on the company.

Nomura initiated coverage on WMS Industries Inc. (WMS). They placed a “Neutral” rating on the company.

3 comments:

noah zeiler said...

Regarding a recent story on Opko Health, with the resent acquisition of the Claros technology, Opko has perhaps one the most attractive “revenue ramps” (according to the likes of Mad Moneys Jim Crammer and others) in the bio-tech sector. Diagnostics account for over 500 billion in revenue world wide, and the technology that opko possesses is nothing short of a “game changer”. For example a simple vitamin d test alone, annually world-wide is performed over est. by 2012 500 million times (500,000 by the Mayo clinic alone in 2009) @ an average of $50.00 per test, you can see why this company’s true value lies in its potential revenues. Opko can currently perform over 20 mainstream diagnostics tests which use to take days or weeks to conclude, now in-house within 10 minutes with greater accuracy, reliability and with less evasiveness than ever before. With only a 1.8 billion dollar market cap…..this stock is “dirt-cheap”. I think that by the summer of 2012 Opko (OPK) will be trading well above the $22.00 to $26.00 price level on anticipated revenues.

The CEO of Opko Health is Dr. Phillip Frost. He has an excellent history of buying, running than selling small bio-tech companies at HUGE profits for early stock holders…. (TEVA) being his last venture before Opko. Over 6000% was made by early investors. Opko will be no exception. This man is not only a genius , but he is also a brilliant, billionaire businessman with an unmatched ability to seek out undervalued bio-tech companies like Claros and run them in such a way as to making them irresistible acquisitions by big pharma companies.

Opko, with Dr. Frost at its’ helm, will soon acquire a large percentage of the 500 billion dollar market share for diagnostics and soon be priced to reflect this revenue. By then I am sure that the stock price will be well into the $50.00 price range or more.

noah zeiler said...

Regarding a recent story on Opko Health, with the resent acquisition of the Claros technology, Opko has perhaps one the most attractive “revenue ramps” (according to the likes of Mad Moneys Jim Crammer and others) in the bio-tech sector. Diagnostics account for over 500 billion in revenue world wide, and the technology that opko possesses is nothing short of a “game changer”. For example a simple vitamin d test alone, annually world-wide is performed over est. by 2012 500 million times (500,000 by the Mayo clinic alone in 2009) @ an average of $50.00 per test, you can see why this company’s true value lies in its potential revenues. Opko can currently perform over 20 mainstream diagnostics tests which use to take days or weeks to conclude, now in-house within 10 minutes with greater accuracy, reliability and with less evasiveness than ever before. With only a 1.8 billion dollar market cap…..this stock is “dirt-cheap”. I think that by the summer of 2012 Opko (OPK) will be trading well above the $22.00 to $26.00 price level on anticipated revenues.

The CEO of Opko Health is Dr. Phillip Frost. He has an excellent history of buying, running than selling small bio-tech companies at HUGE profits for early stock holders…. (TEVA) being his last venture before Opko. Over 6000% was made by early investors. Opko will be no exception. This man is not only a genius , but he is also a brilliant, billionaire businessman with an unmatched ability to seek out undervalued bio-tech companies like Claros and run them in such a way as to making them irresistible acquisitions by big pharma companies.

Opko, with Dr. Frost at its’ helm, will soon acquire a large percentage of the 500 billion dollar market share for diagnostics and soon be priced to reflect this revenue. By then I am sure that the stock price will be well into the $50.00 price range or more.

noah zeiler said...

Regarding a recent story on Opko Health, with the resent acquisition of the Claros technology, Opko has perhaps one the most attractive “revenue ramps” (according to the likes of Mad Moneys Jim Crammer and others) in the bio-tech sector. Diagnostics account for over 500 billion in revenue world wide, and the technology that opko possesses is nothing short of a “game changer”. For example a simple vitamin d test alone, annually world-wide is performed over est. by 2012 500 million times (500,000 by the Mayo clinic alone in 2009) @ an average of $50.00 per test, you can see why this company’s true value lies in its potential revenues. Opko can currently perform over 20 mainstream diagnostics tests which use to take days or weeks to conclude, now in-house within 10 minutes with greater accuracy, reliability and with less evasiveness than ever before. With only a 1.8 billion dollar market cap…..this stock is “dirt-cheap”. I think that by the summer of 2012 Opko (OPK) will be trading well above the $22.00 to $26.00 price level on anticipated revenues.

The CEO of Opko Health is Dr. Phillip Frost. He has an excellent history of buying, running than selling small bio-tech companies at HUGE profits for early stock holders…. (TEVA) being his last venture before Opko. Over 6000% was made by early investors. Opko will be no exception. This man is not only a genius , but he is also a brilliant, billionaire businessman with an unmatched ability to seek out undervalued bio-tech companies like Claros and run them in such a way as to making them irresistible acquisitions by big pharma companies.

Opko, with Dr. Frost at its’ helm, will soon acquire a large percentage of the 500 billion dollar market share for diagnostics and soon be priced to reflect this revenue. By then I am sure that the stock price will be well into the $50.00 price range or more.